Barclays Remains Cautious on Ultragenyx (RARE), Cites Setrusumab Study Analysis Despite 70% Positive Result Outlook

29 11 月, 2025

One Min Read

7 Views

原文: https://finance.yahoo.com/news/barclays-remains-cautious-ultragenyx-rare-165747238.html

Last Update: 29 11 月, 2025

Written By

Other Articles

Previous

Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating

Next

Strategy Inc’s (MSTR) Saylor Sees Upside for Bitcoin Despite a 20% Fall Last Month

Related Posts

Powerball jackpot soars to $1.3 billion. Here’s what the winner will take home after taxes.

1 Min Read

What is force-placed car insurance, and when do lenders require it?

1 Min Read

Do you need collateral for a personal loan? See when it might help.

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept